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Measles, Mumps, and Rubella
Chapters 13, 15, and 20 
Disease
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 Paramyxovirus
• Nasopharynx is primary site of infection
 Incubation period is 10–12 days
 Prodrome is 2–4 days
• 3 Cs – cough, coryza, and conjunctivitis
• Stepwise increase in fever up to 103°F–105°F
• Koplik spots
 Rash occurs 2–4 days after prodrome, 14 days after 
exposure, and persists 5–6 days
• Begins on face and upper neck
• Maculopapular, becomes confluent
• Fades in order of appearance
Measles
Measles Complications
Complication Rate
Diarrhea 8%
Otitis media 7%
Pneumonia 6%
Encephalitis 0.1%
Seizures 0.6–0.7%
Death 0.2%
 Paramyxovirus
─ Nasopharynx and regional lymph nodes are primary sites 
of infection
 Incubation period is 12–25 days
 Prodrome is nonspecific
─ Myalgia
─ Anorexia
─ Malaise
─ Headache
─ Low-grade fever
 Parotitis in 9%–94%, typically occurs within 16–18 
days
 Prevaccine era:  15%–27% of infections were 
asymptomatic
Mumps
Complication Rate
Orchititis 12%–66% in postpubertal males 
(prevaccine)
3%–10% (postvaccine)
Pancreatitis 3.5% (prevaccine)
Unilateral deafness 1/20,000 (prevaccine)
Death 2/10,000 from 1966–1971
Mumps Complications 
 Togavirus
 Incubation period is 14 days (range: 12–23 days)
 Prodrome
• Rare in children
• Low-grade fever in adults
 Maculopapular rash 14–17 days after exposure
 Lymphadenopathy occurs before rash and lasts for 
several weeks
Rubella
Complication Rate
Arthritis or arthralgia May occur in up to 70% of adult women, 
but is rare in children and adult males
Encephalitis 1/6,000 cases
Hemorrhagic manifestations  
(e.g., thrombocytopenic purpura)
1/3,000 cases 
Orchitis, neuritis, progressive 
panencephalitis
Rare
Rubella Complications
 Rubella infection may affect fetal 
organs, causing: 
• Hearing impairment            
• Eye defects
• Cardiac defects
• Microcephaly
• Intellectual disabilities
• Bone alterations
• Liver and spleen damage
 May lead to fetal death or preterm 
delivery
 Severity of damage to fetus 
depends on gestational age
Congenital Rubella Syndrome
Measles Mumps Rubella
Reservoir Human Human Human
Transmission Direct contact with 
infectious droplets 
or by airborne 
spread
Direct contact with 
saliva or respiratory 
droplets 
Direct or droplet 
contact from 
nasopharyngeal 
secretions
Temporal Pattern Peaks in late 
winter/spring
Peaks in late 
winter/spring
Peaks in late 
winter/spring
Communicability 4 days before to 
4 days after rash 
onset
Several days before 
and after onset of 
parotitis
7 days before to 
5–7 days after rash 
onset
Epidemiology

States with Reported Measles Cases (as of 8/1/2019)
The states that have reported 
cases to CDC are Alaska, 
Arizona, California, Colorado, 
Connecticut, Florida, Georgia, 
Idaho, Illinois, Indiana, Iowa, 
Kentucky, Maine, Maryland, 
Massachusetts, Michigan, 
Missouri, New Mexico, Nevada, 
New Hampshire, New Jersey, 
New York, Ohio, Oklahoma, 
Oregon, Pennsylvania, Texas, 
Tennessee, Virginia, and 
Washington.
www.cdc.gov/measles/cases-
outbreaks.html
Measles cases and outbreaks: https://www.cdc.gov/measles/cases-outbreaks.html
 Be vigilant about measles
 Ensure EVERYONE is up to date on MMR vaccination 
• Staff and patients–children, adolescents, and adults 
 Consider measles in patients with febrile rash illness and clinically compatible 
measles symptoms (cough, coryza, and conjunctivitis)
 Ask patients about:
• Recent travel internationally
• Recent travel to domestic venues frequented by international travelers
• Recent contact with international travelers
• History of measles in the community
 Promptly isolate patients with suspected measles
Guidance for Health Care Personnel
www.cdc.gov/measles/hcp/index.html
Measles Resources
www.cdc.gov/measles/index.html,  www.cdc.gov/measles/toolkit/index.html, 
and www.cdc.gov/measles/resources/multimedia.html

U.S. Mumps Cases as of July 19, 2019
Mumps Cases and Outbreaks https://www.cdc.gov/mumps/outbreaks.html
*AL, AK, AR, AZ, CA, CO, 
CT, DE, FL, GA, HI, IA, IL, 
IN, KS, LA, MA, MD, ME, 
MI, MN, MO, MS, MT, 
NC, ND, NE, NJ, NM, NV, 
NY, OH, OK, OR, PA, RI, 
SC, TN, TX, UT, VA, VT, 
WA, WI, WV
**Preliminary data 
reported to CDC. Mumps 
outbreaks are not 
reportable.
* Case count is preliminary and subject to change.
**Cases as of July 19, 2019. Case count is preliminary and subject to change.
https://www.cdc.gov/mumps/outbreaks.html
 Health care professionals should be vigilant about mumps:
• Consider mumps in patients presenting with fever and parotitis
• Promptly isolate patients for 5 days after the glands begin to swell
• Immediately report the suspect mumps case to the health department
• Obtain specimens for testing from patients with suspected mumps, including a 
blood specimen and a buccal or oral swab specimen, which confirms the diagnosis 
 Health care personnel should have documented evidence of immunity
• Refer to “Immunization of Health-Care Personnel: Recommendations of the 
Advisory Committee on Immunization Practices” 
(www.cdc.gov/mmwr/pdf/rr/rr6007.pdf)
Suspect Mumps? 
www.cdc.gov/mumps/hcp.html
Rubella
www.cdc.gov/globalhealth/immunization/infographic/stop_rubella.htm
www.cdc.gov/vaccines/pubs/surv-manual/chpt14-rubella.html
www.cdc.gov/rubella/index.html
Acceptable Presumptive Evidence of Immunity
Routine Students 
(College/
Post High School)
Health Care Personnel International Travelers
(1) Documented age-
appropriate vaccination with 
live measles-, mumps-, and 
rubella-virus-containing 
vaccines, or
(1) Documented doses of 
live measles and mumps 
virus-containing vaccines; 
dose of rubella-virus-
containing vaccine, or
(1) Documented doses of 
live measles and mumps 
virus-containing vaccines; 
dose of rubella-virus-
containing vaccine, or
(1) Documented age-
appropriate vaccination with 
live measles-, mumps-, and 
rubella-virus-containing 
vaccines, or
(2) Laboratory evidence of 
immunity, or
(2) Laboratory evidence of 
immunity, or
(2) Laboratory evidence of 
immunity, or
(2) Laboratory evidence of 
immunity, or
(3) Laboratory confirmation 
of disease
(3) Laboratory confirmation 
of disease
(3) Laboratory confirmation 
of disease
(3) Laboratory confirmation 
of disease
(4) Born before 1957 (except 
rubella for women of 
childbearing age who could 
become pregnant
(4) Born before 1957 (except 
rubella for women of 
childbearing age who could 
become pregnant
(4) Born before 1957 (except 
rubella for women of 
childbearing age who could 
become pregnant
(4) Born before 1957 (except 
rubella for women of 
childbearing age who could 
become pregnant
 Serologic screening before vaccination is not necessary unless the health 
care facility considers it cost-effective
 Postvaccination serologic testing to verify immunity is not recommended
• Documented, age-appropriate vaccination supersedes the results of subsequent 
serologic testing
• MMR vaccination for persons with 2 documented doses of measles- or mumps-
containing vaccine or 1 dose of rubella-containing vaccine with a negative or 
equivocal measles titer is not recommended
• Exception for women of childbearing age
Measles, Mumps, Rubella Serologic Testing
www.cdc.gov/mmwr/pdf/rr/rr6204.pdf
Vaccine
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 MMR (combination vaccine) licensed in 1971
 Highly effective
 Safe (over 50 years of use)
• Low risk of febrile seizures in children 12 to 23 months (1 in 3,000 doses)
• Temporary pain/stiffness in joints (teens or adult women)
• Temporary low platelet count (1 in 30,000 doses)
MMR Vaccine
 Composition Live, attenuated viruses
 Efficacy Measles: 95% at 12 months; 98% at 15 months
Mumps: 88% (range: 31%–95%) (2 doses)
Rubella: 95% or more (1 dose)
 Schedule 2 doses given subcutaneously
MMR Vaccine
https://emergency.cdc.gov/coca/ppt/2019/slides_052119_Measles.pdf
 Composition Live, attenuated measles, mumps, rubella, and 
varicella vaccines
7 to 8 times as much vaccine virus as monovalent 
varicella vaccine
 Efficacy Inferred from that of MMR vaccine and varicella 
vaccine on the basis of noninferior immunogenicity
 Schedule 2 doses given subcutaneously 
MMRV Vaccine
 Routine administration
 Medical indications
Child/Adolescent Schedule
 First dose at 12–15 months of age
• Minimum age is 12 months
• Doses given before 12 months of age are not counted as valid
o Infants as young as 6 months should receive MMR before international travel* 
o Revaccinate at 12 months of age or older
 Second dose at 4–6 years of age
• May be administered before age 4 years (observe 4-week minimum interval)
• Intended to produce measles and/or mumps immunity in persons who failed to 
respond to the first dose 
• People who received 2 doses of MMR vaccine as children according to the U.S. 
vaccination schedule are considered protected for life
MMR Recommendations for Children and Adolescents 
(Birth through 18 Years)
*ACIP off-label recommendation www.cdc.gov/mmwr/pdf/rr/rr6204.pdf
 First dose at 12–47 months of age
• Minimum age is 12 months
• Can be given as MMR and VAR separately or MMRV
 Second dose at 15 months–12 years of age
• MMRV generally preferred
• May be given any time before 13th birthday at least 3 months (minimum interval) 
after the first dose
• Not approved for use in persons 13 years of age and older
MMRV Vaccine
www.cdc.gov/mmwr/pdf/rr/rr5903.pdf
 Routine administration
 Medical Indications
Adult Schedule
 Adults born in 1957 or later without acceptable evidence of immunity 
to measles, mumps, or rubella should receive 1 dose of MMR
 A routine second dose of MMR vaccine at least 28 days after the first 
dose is recommended for adults who are:
• College and post-high-school students
• Working in medical facilities
• International travelers
 Adults born before 1957 are generally presumed immune to measles, 
mumps, and rubella
ACIP Immunization Recommendations: Adults 
 Adults without acceptable evidence of immunity to measles, mumps, or 
rubella who work in a health care facility should receive 2 doses of MMR
─ Personnel born before 1957 without acceptable evidence of immunity to measles, 
mumps, or rubella should be considered for vaccination with 2 doses of MMR for 
measles or mumps, or 1 dose for rubella 
MMR Recommendations: Adults 
Clinical 
Considerations
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 Vaccinated before the first birthday
 Vaccinated with inactivated (killed) measles vaccine (KMV) or measles 
vaccine of unknown type from 1963 through 1967 
 Vaccinated with immune globulin (IG) in addition to a further attenuated 
strain or vaccine of unknown type (revaccination not necessary if IG given 
with Edmonston B vaccine)
 Vaccinated before 1979 with either inactivated mumps vaccine or mumps 
vaccine of unknown type who are at high risk for mumps infection (e.g., 
work in a health care facility) should be considered for revaccination with 2 
doses of MMR
MMR Revaccination Indications
Mumps: January 2018 ACIP Recommendation
https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html
*Off-label recommendation
 Infants 6 through 11 months of age should receive one dose of MMR 
vaccine
 Children 12 months of age or older should have documentation of two
doses of MMR vaccine
 Teenagers and adults born during or after 1957 without evidence of 
immunity against measles should have documentation of two doses of 
MMR vaccine
 Ask patients about plans for international travel as part of your routine 
screening process
International Travel
 HCP with 2 documented, appropriately spaced doses of MMR are not 
recommended to be serologically tested for immunity
 IF they are tested and results are negative or equivocal for measles, 
mumps, and/or rubella, NO additional MMR doses are recommended
 Do NOT test persons with documented history of MMR vaccination  
Health Care Personnel: 
MMR Vaccination and Serologic Testing
 2 doses of MMR vaccine should be considered for unvaccinated HCP 
born before 1957 who do not have laboratory evidence of disease or 
immunity to measles and/or mumps 
 1 dose of MMR vaccine should be considered for HCP with no 
laboratory evidence of disease or immunity to rubella 
HCP Born Before 1957 
 Health care facilities should recommend 2 doses of MMR vaccine at the 
appropriate interval for unvaccinated health care personnel regardless 
of birth year who lack laboratory evidence of measles or mumps 
immunity or laboratory confirmation of disease
 A third dose of MMR can be administered to adults who previously 
received 2 or more doses of mumps-containing vaccine and are 
identified by public health authority to be at increased risk for mumps 
in an outbreak
HCP and Outbreaks 
 If a health care worker develops a rash and low-grade fever after MMR 
vaccination, is s/he infectious? 
 Approximately 5 to 15% of susceptible people who receive MMR vaccine 
will develop a low-grade fever and/or mild rash 7 to 12 days after 
vaccination. However, the person is not infectious, and no special 
precautions (such as exclusion from work) need to be taken.
What Do You Think? 
 Preparation
• MMR-containing vaccines must be reconstituted 
BEFORE administering
• Use ONLY the diluent supplied by the 
manufacturer
 Route: Subcutaneous injection
• Needle gauge:  23–25 gauge
• Needle length:  5/8 inch
 Site: Upper outer triceps of the arm or the 
thigh
MMR and MMRV Administration
45°
Angle
 Wrong diluent used to reconstitute vaccine
• Dose does NOT count and should be repeated ASAP 
 Wrong route
• Administered intramuscularly instead of subcutaneously
 MMRV administered after the age of 12 years
• Dose counts if the minimum interval has been met 
 Always remember – store vaccine according to the manufacturer’s 
recommendations and use a new needle and syringe for each patient
MMR and MMRV Administration Errors
 If given within 72 hours of exposure, MMR vaccine might protect or 
modify clinical course of measles (preferable to IG for persons >12 
months if given within 72 hours of exposure)
 If administered within 6 days of exposure, IG can prevent or modify 
measles in persons who are nonimmune
• Not indicated for persons who have received 1 dose of measles-containing vaccine 
at age ≥12 months, unless they are severely immunocompromised 
 Postexposure MMR vaccination or IG not shown to prevent or alter the 
clinical severity of rubella or mumps and is not recommended 
Measles, Mumps, Rubella Postexposure Prophylaxis
 History of anaphylactic reaction to neomycin
 History of severe allergic reaction to any component of the vaccine
 Pregnancy
 Moderate or severe acute illness
 Recent blood product
 Personal or family (i.e., sibling or parent) history of seizures of any 
etiology 
• Should be vaccinated with separate MMR and varicella vaccines, not MMRV
MMR and MMRV Contraindications and Precautions
*ACIP off-label recommendation; Vaccine package insert states 3 months
 Immunosuppression
• HIV 
o Prevaccination HIV testing not recommended
o MMR recommended for persons who do not have evidence of current severe 
immunosuppression
o Revaccination recommended for persons with perinatal HIV infection who were vaccinated 
before establishment of effective antiretroviral therapy (ART) with 2 appropriately spaced doses 
of MMR vaccine once effective ART has been established
o MMRV not for use in persons with HIV infection
• Low-dose steroids – vaccinate anytime
• Leukemia in remission without chemotherapy for 3 months – vaccinate
• Hematopoietic cell transplant (HCT) recipient who is immunocompetent
MMR Vaccine Contraindications and Precautions
General Best Practice Guidelines for Immunization: www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
 Apply TST or IGRA at same visit as MMR or 
MMRV
 Delay TST or IGRA at least 4 weeks (28 days) if 
MMR or MMRV given first 
 Apply TST first and administer MMR or MMRV 
when skin test read (least favored option 
because receipt of MMR or MMRV is delayed)
Tuberculin Skin Testing (TST)* or Tuberculosis Interferon-
Gamma Release-Assay (IGRA) and MMR or MMRV Vaccines
*Previously called PPD
 Fever 5%–15% (measles)
 Rash, pruritis, purpura 5% (measles)
 Thrombocytopenia 1/30,000–40,000 doses (measles)
 Lymphadenopathy Rare (rash, pruritis, purpura)
 Allergic reactions Rare
 Parotitis Rare (mumps)
 Hearing loss Rare (mumps)
MMR Vaccine Adverse Reactions
 Similar to MMR
 Higher risk for fever and febrile seizures 5–12 days after the first dose among 
children 12–23 months of age
• 1 additional febrile seizure occurred 5–12 days after vaccination per 2,300–2,600 children 
compared with children who received first dose as MMR and varicella vaccine separately
 Fever of 102°F or higher 
• 22% of MMRV recipients
• 15% with separate injections
 Increased risk of febrile seizures has not been observed following use of 
MMRV as the second dose in the MMR and varicella series
MMRV Vaccine Adverse Reactions
MMR Vaccine Safety
“The committee concludes that the 
evidence favors rejection of a causal 
relationship between MMR vaccine and 
autism.” Institute of Medicine, 2004
Vaccine safety information: https://www.cdc.gov/vaccinesafety/index.html 
www.nap.edu/catalog/10997/immunization-safety-review-vaccines-and-autism
www.cdc.gov/measles/cases-outbreaks.html
 Store in the refrigerator between 2°C and 8°C 
(36°F and 46°F) 
• May also be stored in the freezer
• Protect vaccine from light by keeping in the original 
packaging with the lid closed
 Store diluent at room temperature or 
refrigerate
 Discard if not used within 8 hours after 
reconstitution
• Do not fill syringe with reconstituted vaccine until 
ready to administer
MMR Storage and Handling
 Store in the freezer between -50°C and -15°C (-58°F and 
+5°F) 
• Do NOT use dry ice
• Protect vaccine from light
• Vaccine may be stored at refrigerator temperature (2°C and 
8°C or between 36°F and 46°F) for up to 72 continuous hours 
after removal from freezer
 Store diluent at room temperature or refrigerate
 If not used immediately, the reconstituted vaccine may be 
stored at room temperature, protected from light, for up 
to 30 minutes
• Do not freeze reconstituted vaccine
 Discard if not used within 30 minutes after reconstitution
• Do not fill syringe with reconstituted vaccine until ready to 
administer
MMRV Storage and Handling
 A nursing student had MMR titers done before he started school. His 
titers came back negative. He has 2 documented doses of MMR after 1 
year of age, separated by more than 4 weeks.  How many doses of 
MMR should we administer? 
• One 
• Two
• None 
What Do You Think?
